Abstract Number: 252 • 2019 ACR/ARP Annual Meeting
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
ACR Meeting Abstracts